TIMER2.0 analysis demonstrated a significant difference in FOXO3 mRNA expression between tumor and adjacent normal tissues across several cancers, including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), kidney chromophobe (KICH), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA) (P < 0.05, Figure 1). This evidence concerns the gene FOXO3 and gastric adenocarcinoma.